马来酸曲美布sement汀复方制剂药效研究

目的：观察马来酸曲美布汀复方制剂对胃排空及小肠推进和蛋白质消化能力的影响以及其急性毒性作用。方法：采用营养性半固体灌胃法，检测马来酸曲关布汀复方制剂对小鼠胃内残留率、小肠推进率的影响；采用双缩脲法测蛋白量，检测马来酸曲美布汀复方制剂对蛋白质消化能力的影响；采用改进寇氏法进行马来酸曲美布汀复方制剂的急性毒性实验。结果：与模型组比较，马来酸曲美布汀复方制剂各组胃内残留率降低，小肠推进率升高（P〈0．05）；与空白对照组比较，马来酸曲关布汀复方制剂各组蛋白质的胃内消化率明显增加（P〈0．05）；马来酸曲美布汀复合制剂的5个剂量组动物的死亡率随剂量由低到高依次为0％、10％、40％、90％和100％。结论：马来酸曲美布汀复方制剂可以对抗阿托品所致胃肠道运动抑制，能增强对蛋白质的消化能力。小鼠一次灌胃给药的LD，0为（2．89±0．35）g／kg；95％可信限为2．56～3．27g／kg。

Potency Reasearch on Trimebutine Maleate Compound Preparation

Objective： To observe the effect of trimebutine maleate compound preparation on gastric emptying, small intestine advancing and protein digestion as well as its role in acute toxicity. Method： Nutritional semi-solid filling regimens was adopted to test the gastric residual rate and small intestine advancing rate ; biuret protein test was used to detect impact of protein digestion; improved Karber method was applied to test the acute toxicity. Result： Compared with model control group, trimebutine maleate compound preparation in each group significantly reduced the rate of gas- tric residue while increasing the small intestine advancing rate （P 〈 0.05 ） ; compared with the blank control group, the protein digestibility of trimebutine maleate compound preparation group increased significantly （ P 〈 0.05 ） ; the mortality of 5 trimebutine maleate compound preparation groups with different doses were 0% , 10% ,40% ,90% and 100% , re- spectively. Conclusion： Trimebutine maleate compound preparation can not only reduce the inhibition of gastrointestinal tract movement due to atropine, but can enhance the digestion of proteins. LD50 for oral administration of mice is （2.89 ±0.35 ） g/kg ; 95% confidence limit of 2.56 - 3.27 g/kg.